CCL24+monocytes drives resistance to anti-PD-L1 blockade in hepatocellular carcinoma

被引：0
|
作者：
Deng, Haijing
Sit, Grace Fu-Wan
Cheu, Jacinth Wing-Sum
Zhang, Yan
Liu, Cindy Xinqi
Chen, Yiling
Ooi, Zher Yee
Yuen, Vincent Wai-Hin
Ng, Irene Oi-Lin
Wong, Carmen Chak-Lui
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2024年 / 12卷 / 10期
关键词：
D O I：
10.1158/2326-6074.TUMIMM24-B018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B018
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
    Li, Huawei
    You, Jia
    Wei, Yuanfeng
    Zheng, Lingnan
    Yang, Ju
    Xu, Jingyi
    Li, Yue
    Li, Zhaojun
    Yang, Xi
    Yi, Cheng
    PHYTOMEDICINE, 2024, 123
  • [22] Anti-PD-L1 immunotherapy inhibits the progression of sorafenib acquired resistant hepatocellular carcinoma by inducing immune activation
    Xu, D.
    Zhu, Y.
    Yang, J.
    Zhang, Z.
    Li, T.
    Yang, J.
    Dong, Q.
    Qin, L.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1748 - 1749
  • [23] Berberine in combination with anti-PD-L1 suppresses hepatocellular carcinoma progression and metastasis via Erk signaling pathway
    Miao, Ganggang
    Zhang, Zhiyu
    Wang, Meiyan
    Gu, Xingwei
    Xiang, Dongxiao
    Cao, Hongyong
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (01): : 103 - 112
  • [24] Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
    Bonan Zhao
    Zhipeng Dong
    Weixing Liu
    Fangning Lou
    Qiyan Wang
    Hao Hong
    Yue Wang
    Journal of Nanobiotechnology, 19
  • [25] Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
    Zhao, Bonan
    Dong, Zhipeng
    Liu, Weixing
    Lou, Fangning
    Wang, Qiyan
    Hong, Hao
    Wang, Yue
    JOURNAL OF NANOBIOTECHNOLOGY, 2021, 19 (01)
  • [26] Combination of transcatheter arterial chemoembolization and anti-PD-L1 liposomes therapy suppressed hepatocellular carcinoma progression in mice
    Li, Jie
    Zhang, Lijuan
    Tao, Yun
    Sun, Zongqiong
    Ge, Yuxi
    Hu, Shudong
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 189
  • [27] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [28] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [29] Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma
    Netto, George J.
    LANCET, 2016, 387 (10031): : 1881 - 1882
  • [30] Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
    Faiena, Izak
    Cummings, Amy L.
    Crosetti, Anna M.
    Pantuck, Allan J.
    Chamie, Karim
    Drakaki, Alexandra
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 209 - 215
12345